The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Insights into the Management of Giant Cell Arteritis

New Insights into the Management of Giant Cell Arteritis

January 28, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Over the past 10 years, researchers have uncovered significant evidence supporting the diagnosis and treatment of large vessel vasculitis. Now, rheumatologists can manage giant cell arteritis (GCA) cases with more standardized diagnostic imaging tools, newer therapies and optimized therapeutic and monitoring strategies. Imaging has also been increasingly recognized as important in GCA diagnosis, and tocilizumab was recently identified as a novel therapeutic option. This new information has been included in the latest update of the 2009 EULAR recommendations on the management of large vessel vasculitis.1

You Might Also Like
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
Also By This Author
  • Do Patients with Ankylosing Spondylitis in Remission Still Need TNF Inhibitors?

Sara Monti, MD, a rheumatologist at Fondazione IRCCS Policlinico San Matteo, Italy, and colleagues performed the literature reviews that support the 2018 update of the EULAR recommendations on the management of large vessel vasculitis.2 This thorough review of evidence published on the diagnosis, monitoring and treatment of GCA included studies published through December 2017. The systematic literature review was published in the September 2019 issue of RMD Open.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The team identified 287 eligible articles on large vessel vasculitis, of which 138 studies focused on GCA. Most of the studies had low levels of evidence. In the review, researchers explained that one of their challenges was that rheumatologists lack standardized definitions for the different GCA disease patterns. This lack of standardization made it difficult to compare the studies. Despite this limitation, the investigators report the main disease patterns for GCA appear to be cranial and large vessel GCA.

The authors found two retrospective cohort studies that compared conventional clinical practices with a fast-track approach that integrates clinical evaluation with ultrasonographic assessment of the temporal and axillary arteries. The use of a fast-track approach to diagnose GCA significantly lowered the risk—relative to historical efforts—of ischemic complications, such as permanent loss of vision.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers identified 13 retrospective, observational cohort papers of which only three prospective studies focused on the diagnostic role of temporal artery biopsy and on the associated clinical features. After reviewing these papers, they concluded that, although temporal artery biopsy is a highly specific test to confirm a GCA diagnosis, the data supporting a prognostic role for temporal artery biopsy on disease course outcome are inconsistent. The researchers also noted that there are still no reliable diagnostic or prognostic biomarkers for GCA.

Treatment
The systematic review confirms the need to initiate glucocorticoid therapy promptly after GCA is identified as a potential diagnosis. The researchers found no high-quality evidence on the most appropriate starting dose, route of administration, tapering and duration of glucocorticoids. However, because patients with GCA have an increased risk of dose-dependent, glucocorticoid-related adverse events, researchers suggested the addition of methotrexate or tocilizumab may be helpful in reducing relapse rates and decreasing the need for glucocorticoids.

Pages: 1 2 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: EULAR, GCA, giant cell arteritis (GCA), guideline, large-vessel vasculitis, recommendations, tocilizumab

You Might Also Like:
  • How to Manage Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
  • Update on the Management of Takayasu Arteritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)